This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oncothyreon Announces Presentation Of PX-866 Clinical Data At American Association Of Clinical Oncology Annual Meeting

Phase 2 Trial of PX-866 in Patients with Glioblastoma Multiforme

Interim data from an open-label single-arm Phase 2 trial of PX-866 in patients with glioblastoma multiforme (GBM), a type of brain cancer, were presented by Marshall W. Pitz, M.D., of CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba. The Phase 2 trial is being conducted at 7 Canadian centers by the NCIC Clinical Trials Group (NCIC CTG), Queen's University in Kingston, Canada, in patients whose brain tumor is in first relapse during or following primary therapy.  The trial has a two-stage design, with progression to the second stage dependent upon achieving a pre-specified endpoint of response or lack of early progression.

Seventeen patients were enrolled in the first stage of the trial and were included in this presentation.  PX-866 was well-tolerated in the study, with the most common adverse events being diarrhea and reversible liver enzyme elevation.  All patients were evaluable for response, with one patient having a partial response and six patients with stable disease, three of whom remained on therapy at the time of the report.  These efficacy data met the pre-specified endpoint, and the trial is currently enrolling a planned additional 15 patients in the second stage.

PX-866 Phase 2 Program Update

In addition to the above mentioned trial in patients with GBM, the NCIC CTG is also conducting a Phase 2 trial in up to 40 patients with metastatic or recurrent castration resistant prostate cancer who have not received prior chemotherapy.  The primary endpoint of this single-arm screening trial is the proportion of patients with lack of disease progression at 12 weeks from the initiation of therapy with PX-866. The trial has a two-stage design, with progression to the second stage dependent upon achieving a pre-specified endpoint of lack of early progression.  The trial has completed enrollment in the first stage of the study and the interim analysis is currently pending.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs